Zimmer Biomet — Feb 10, 2026 release

Page 5 of 25   Financial Guidance The Company is providing the following full-year 2026 financial guidance: Projected Year Ending December 31, 2026     2026 Reported Revenue Change 2.5% - 4.5% Foreign Currency Exchange Impact +0.50% 2026 Constant Currency Revenue Change 2.0% - 4.0% 2026 Organic Constant Currency Revenue Change (1) 1.0% - 3.0% Adjusted Diluted EPS (2) $8.30 - $8.45   (1) Excludes the projected impact of the Paragon 28 acquisition through the one-year anniversary of the acquisition date, which is estimated to be approximately 100bps. (2) This measure is a non-GAAP financial measure for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts. See “Forward-Looking Non-GAAP Financial Measures” below, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that this forward-looking non-GAAP financial measure may be materially different from the corresponding GAAP financial measure. Conference Call The Company will conduct its fourth quarter and full-year 2025 investor conference call today, February 10, 2026, at 8:30 a.m. ET. The audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com . It will be archived for replay following the conference c